S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

NASDAQ:GRTSGritstone Oncology Stock Price, Forecast & News

$6.75
+0.03 (+0.45 %)
(As of 04/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.51
Now: $6.75
$7.21
50-Day Range
$5.47
MA: $7.20
$10.45
52-Week Range
$5.42
Now: $6.75
$15.24
Volume142,940 shs
Average Volume159,564 shs
Market Capitalization$249.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Read More
Gritstone Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRTS
CUSIPN/A
CIKN/A
Phone510-871-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.36 million
Book Value$3.75 per share

Profitability

Net Income$-94,430,000.00
Net Margins-2,163.41%

Miscellaneous

Employees113
Market Cap$249.59 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive GRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.


Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions

How has Gritstone Oncology's stock been impacted by COVID-19 (Coronavirus)?

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GRTS stock has increased by 1.2% and is now trading at $6.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gritstone Oncology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology.

When is Gritstone Oncology's next earnings date?

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Gritstone Oncology.

How were Gritstone Oncology's earnings last quarter?

Gritstone Oncology Inc (NASDAQ:GRTS) released its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.08. The company had revenue of $0.88 million for the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,163.41% and a negative return on equity of 62.40%. View Gritstone Oncology's earnings history.

What price target have analysts set for GRTS?

3 Wall Street analysts have issued twelve-month target prices for Gritstone Oncology's stock. Their forecasts range from $17.00 to $17.00. On average, they expect Gritstone Oncology's share price to reach $17.00 in the next year. This suggests a possible upside of 151.9% from the stock's current price. View analysts' price targets for Gritstone Oncology.

Has Gritstone Oncology been receiving favorable news coverage?

News articles about GRTS stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gritstone Oncology earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutGritstone Oncology.

Are investors shorting Gritstone Oncology?

Gritstone Oncology saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,170,000 shares, a decrease of 8.1% from the February 27th total of 3,450,000 shares. Based on an average trading volume of 155,800 shares, the short-interest ratio is currently 20.3 days. Approximately 24.8% of the company's stock are sold short. View Gritstone Oncology's Current Options Chain.

Who are some of Gritstone Oncology's key competitors?

What other stocks do shareholders of Gritstone Oncology own?

Who are Gritstone Oncology's key executives?

Gritstone Oncology's management team includes the following people:
  • Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)
  • Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)
  • Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)
  • Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)
  • Dr. Roman Yelensky, Exec. VP & CTO (Age 40)

When did Gritstone Oncology IPO?

(GRTS) raised $85 million in an initial public offering (IPO) on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone Oncology's stock symbol?

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

How do I buy shares of Gritstone Oncology?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gritstone Oncology's stock price today?

One share of GRTS stock can currently be purchased for approximately $6.75.

How big of a company is Gritstone Oncology?

Gritstone Oncology has a market capitalization of $249.59 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe. View additional information about Gritstone Oncology.

What is Gritstone Oncology's official website?

The official website for Gritstone Oncology is http://www.gritstoneoncology.com/.

How can I contact Gritstone Oncology?

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 300, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Featured Article: Trading Ex-Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel